We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+9.28%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$612M
AUM Growth
-$64.3M
Cap. Flow
-$69.2M
Cap. Flow %
-11.31%
Top 10 Hldgs %
55.01%
Holding
54
New
9
Increased
9
Reduced
21
Closed
8

Top Buys

1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$14.4M
2
IART icon
Integra LifeSciences
IART
+$12.3M
3
ZGNX
Zogenix, Inc.
ZGNX
+$12.1M
4
MDCO
Medicines Co
MDCO
+$11.3M
5
ADMA icon
ADMA Biologics
ADMA
+$3.08M

Top Sells

1
HRTX icon
Heron Therapeutics
HRTX
+$23.3M
2
CORI
Corium International, Inc.
CORI
+$10.7M
3
AVDL
Avadel Pharmaceuticals
AVDL
+$9.16M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.72M
5
SCTL
Societal CDMO, Inc. Common Stock
SCTL
+$6.07M

Sector Composition

1 Healthcare 91.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDTX
26
DELISTED
Cidara Therapeutics
CDTX
$5.83M 0.95%
42,870
+1,850
+5% +$281K
TTPH
27
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$5.6M 0.92%
44,455
-545
-1% -$69.8K
VCYT icon
28
Veracyte
VCYT
$4.72B
$4.87M 0.8%
746,358
-274,474
-27% -$2.04M
NUVA
29
DELISTED
NuVasive, Inc.
NUVA
$4.8M 0.79%
82,100
-5,900
-7% -$335K
AMRN
30
Amarin Corp
AMRN
$292M
$4.61M 0.75%
57,522
-24,100
-30% -$1.66M
HZNP
31
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$4.38M 0.72%
+300,000
New +$4.21M
ACGN
32
DELISTED
Aceragen Inc
ACGN
$4.29M 0.7%
14,946
-2,939
-16% -$839K
BAX icon
33
Baxter International
BAX
$11.7B
$4.22M 0.69%
65,300
– –
ADMA icon
34
ADMA Biologics
ADMA
$2.02B
$3.54M 0.58%
+1,102,200
New +$3.08M
MDWD icon
35
MediWound
MDWD
$188M
$2.23M 0.36%
71,429
– –
CGNT
36
DELISTED
Cogentix Medical, Inc.
CGNT
$2.11M 0.35%
670,812
-333,540
-33% -$961K
RGLS
37
DELISTED
Regulus Therapeutics
RGLS
$1.57M 0.26%
12,578
-23,210
-65% -$2.94M
CFRX
38
DELISTED
ContraFect Corporation
CFRX
$1.24M 0.2%
1,540
-1,849
-55% -$1.53M
TVTX icon
39
CALL
Travere Therapeutics
TVTX
$5.27B
$1.09M 0.18%
+51,900
New +$1.19M
AGRX
40
DELISTED
Agile Therapeutics
AGRX
$964K 0.16%
+179
New +$1.67M
TPST icon
41
Tempest Therapeutics
TPST
$15.4M
$770K 0.13%
188
– –
NSTG
42
DELISTED
NanoString Technologies, Inc.
NSTG
$747K 0.12%
+100,000
New +$948K
VCEL icon
43
Vericel Corp
VCEL
$2.38B
$472K 0.08%
+86,558
New +$399K
ATEC icon
44
Alphatec Holdings
ATEC
$1.31B
$387K 0.06%
+145,514
New +$466K
SSKN
45
DELISTED
Strata Skin Sciences
SSKN
$250K 0.04%
20,335
+15,552
+325% +$217K
ALNY icon
46
Alnylam Pharmaceuticals
ALNY
$35.7B
– –
-74,208
Closed -$8.72M
FOLD
47
DELISTED
Amicus Therapeutics
FOLD
– –
-141,000
Closed -$2.13M
ACH
48
Accendra Health
ACH
$266M
– –
-133,700
Closed -$3.9M
ZBH icon
49
CALL
Zimmer Biomet
ZBH
$17.6B
– –
-206,000
Closed -$23.4M
ZBH icon
50
Zimmer Biomet
ZBH
$17.6B
– –
-50,470
Closed -$5.74M
1
2
3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q4 2017 Portfolio in Review

As of Q4 2017, Broadfin Capital held 54 positions worth $612M, down 9.5% from $676M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Broadfin Capital withdrew a net $69.2M in Q4 2017, closing 8 positions and reducing 21 holdings. Its most notable exit was Alnylam Pharmaceuticals, an estimated $8.72M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 88% a quarter earlier.

Against the trend, Broadfin Capital opened a new position in GW Pharmaceuticals Plc American Depositary Shares worth $16.2M.

  • Broadfin Capital's largest Q4 2017 buy was GW Pharmaceuticals Plc American Depositary Shares: 122,930 shares worth $16.2M.
  • Broadfin Capital added most to Integra LifeSciences in Q4 2017, an estimated $12.3M increase.
  • Broadfin Capital's biggest Q4 2017 reduction was Heron Therapeutics, cutting an estimated $23.3M.
  • Broadfin Capital fully exited Alnylam Pharmaceuticals in Q4 2017, selling an estimated $8.72M.
  • Broadfin Capital's ten largest holdings make up 55% of its $612M portfolio in Q4 2017.
  • Broadfin Capital opened 9 new positions and closed 8 in Q4 2017.
  • Broadfin Capital's portfolio value fell 9.5% quarter-over-quarter to $612M.

Based on Broadfin Capital's 13F filing for Q4 2017, filed 13 Feb 2018.